KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查 入排置信度 0.98

Efficacy and safety of anifrolumab in patients with systemic lupus erythematosus without prior immunosuppressant use: post hoc analysis of phase 3 TULIP-1 and TULIP-2 trials.

Andrea Doria, Ronald F van Vollenhoven, Eric F Morand, Marta Mosca, Jonatan Nåtman, Miina Waratani, Jacob Knagenhjelm, Catharina Lindholm, Danuta Kielar

Lupus Sci Med 13(1) e001891

PMID41951251
PMCIDPMC13064137
DOI10.1136/lupus-2025-001891
发表日期2026-04-08
入排依据:未发现恶性肿瘤人群证据。
入排复审未纳入:未发现恶性肿瘤人群证据。
摘要

摘要

OBJECTIVE: Although current treatment recommendations for systemic lupus erythematosus (SLE) provide the option for biologic agents without prior failure of immunosuppressants (IS), data on this treatment approach are limited. This study evaluates the efficacy and safety of anifrolumab by IS exposure. METHODS: Pooled data from the Phase 3 TULIP-1 (NCT02446912) and TULIP-2 (NCT02446899) trials were analysed post hoc to compare patients with moderate-to-severe SLE treated with intravenous anifrolumab 300 mg or placebo alongside standard therapy by reported IS use. Efficacy outcomes by IS use included Definition of Remission in SLE (DORIS) remission and Lupus Low Disease Activity State (LLDAS) attainment, analysed using a stratified Cochran-Mantel-Haenszel approach; all p values are nominal. Safety was summarised descriptively. RESULTS: In this analysis, 257 patients had no reported IS use (IS-inexperienced; anifrolumab 300 mg, n=127; placebo, n=130), and 469 were IS-experienced (anifrolumab 300 mg, n=233; placebo, n=236). At Week 52, DORIS remission and LLDAS attainment rates were higher with anifrolumab versus placebo in both IS subgroups (DORIS, IS-inexperienced, 16.2% vs 6.0%, p=0.0242; IS-experienced, 14.6% vs 7.3%, p=0.0304; LLDAS, IS-inexperienced, 34.0% vs 26.2%, p=0.1718; IS-experienced, 27.7% vs 16.2%, p=0.0038). Anifrolumab was well tolerated, regardless of reported IS history; safety was more favourable among IS-inexperienced versus IS-experienced patients. CONCLUSIONS: This post hoc analysis of pooled TULIP-1/TULIP-2 data supports the efficacy and tolerability of anifrolumab in patients with moderate-to-severe SLE regardless of IS treatment history.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。